Invivyd (NASDAQ:IVVD) surged 25.22% on analyst upgrade and regulatory progress

Invivyd (NASDAQ:IVVD) surged 25.2174% in pre-market trading on Dec. 23, 2025, following a strategic analyst upgrade and key regulatory progress.

BTIG analyst Thomas Shrader initiated coverage with a Buy rating and a $10 price target, highlighting the company’s antibody development expertise and the potential of its VYD2311 candidate to outperform mRNA vaccines. The firm cited VYD2311’s focus on stable viral epitopes and a pending Phase 3 trial readout by late 2026 as catalysts. H.C. Wainwright also raised its price target to $10, maintaining a Buy rating after the company unveiled its REVOLUTION clinical program.

Regulatory momentum fueled optimism, as the FDA approved Invivyd’s Investigational New Drug application for VYD2311, advancing trials DECLARATION and LIBERTY. The firm also secured $125 million through a public offering of 44 million shares, with Cantor Fitzgerald acting as lead manager. Additionally, Invivyd’s PEMGARDA, authorized in 2024, demonstrated 80% efficacy against current variants, contrasting with 40-50% effectiveness of mRNA vaccines in healthy individuals.

Analysts believe the recent developments position Invivyd to become a key player in the next-generation vaccine market. The company's Phase 3 trial timeline and positive early trial results could attract further investment and strategic partnerships in early 2026.

Investors are advised to monitor upcoming trial data and FDA feedback for potential volatility and investment opportunities.